Free Trial

Organon & Co. (NYSE:OGN) Receives $18.00 Average PT from Brokerages

Organon & Co. logo with Medical background

Organon & Co. (NYSE:OGN - Get Free Report) has received a consensus rating of "Moderate Buy" from the six analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $18.00.

OGN has been the topic of a number of recent research reports. Piper Sandler lowered their target price on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Morgan Stanley cut their price target on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. BNP Paribas raised Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. Barclays cut their price target on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Finally, Evercore ISI cut Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd.

View Our Latest Report on Organon & Co.

Organon & Co. Trading Up 4.3%

Shares of NYSE OGN traded up $0.40 during midday trading on Friday, hitting $9.55. The company's stock had a trading volume of 1,595,558 shares, compared to its average volume of 3,264,947. The business's 50 day moving average is $11.15 and its two-hundred day moving average is $13.91. The firm has a market cap of $2.48 billion, a P/E ratio of 2.86, a price-to-earnings-growth ratio of 0.90 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $8.01 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.13. The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.53 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Organon & Co.'s revenue was down 6.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.22 earnings per share. As a group, equities research analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Monday, May 12th will be paid a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend is Monday, May 12th. Organon & Co.'s dividend payout ratio is presently 2.78%.

Insider Buying and Selling

In other Organon & Co. news, insider Kirke Weaver bought 8,045 shares of the business's stock in a transaction on Tuesday, May 6th. The shares were purchased at an average price of $9.21 per share, with a total value of $74,094.45. Following the completion of the acquisition, the insider now directly owns 52,489 shares of the company's stock, valued at approximately $483,423.69. The trade was a 18.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Daniel Karp purchased 3,500 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were acquired at an average cost of $8.24 per share, for a total transaction of $28,840.00. Following the acquisition, the vice president now owns 46,669 shares of the company's stock, valued at approximately $384,552.56. The trade was a 8.11% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 102,345 shares of company stock valued at $902,430. 1.96% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OGN. Barclays PLC raised its holdings in Organon & Co. by 238.0% during the third quarter. Barclays PLC now owns 119,483 shares of the company's stock worth $2,285,000 after purchasing an additional 84,136 shares in the last quarter. HB Wealth Management LLC grew its position in Organon & Co. by 64.2% in the fourth quarter. HB Wealth Management LLC now owns 18,114 shares of the company's stock worth $270,000 after buying an additional 7,081 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after buying an additional 672 shares during the last quarter. Impact Partnership Wealth LLC grew its position in Organon & Co. by 43.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 18,871 shares of the company's stock worth $282,000 after buying an additional 5,736 shares during the last quarter. Finally, DGS Capital Management LLC acquired a new position in Organon & Co. in the fourth quarter worth approximately $235,000. Institutional investors own 77.43% of the company's stock.

Organon & Co. Company Profile

(Get Free Report

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Featured Articles

Analyst Recommendations for Organon & Co. (NYSE:OGN)

Should You Invest $1,000 in Organon & Co. Right Now?

Before you consider Organon & Co., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.

While Organon & Co. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines